SecBot SecBot
SECBOTREPLAY Home › Report › BBIO

BBIO · BridgeBio announced first patient dosed in ASCEND-ATTR, a Phase 3b/4…

BridgeBio Pharma, Inc. · PRESS-RELEASE filed Aug 26, 2026 at 07:30 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Aug 26, 2026 at 07:30 ET

BridgeBio announced first patient dosed in ASCEND-ATTR, a Phase 3b/4 study of acoramidis in ATTR-CM, designed to assess long-term effects on cardiac structure, function, and amyloid burden. This builds on encouraging CMR substudy data from the Phase 3 ATTRibute-CM trial suggesting potential disease reversal. The study is prospective and open-label, enrolling ~150 patients with annual imaging over 36 months.

  • First participant dosed in ASCEND-ATTR, a Phase 3b/4 open-label study of acoramidis in ATTR-CM
  • Study will enroll ~150 participants with annual CMR and echocardiography over 36 months
  • Primary endpoint: responder status at Month 36 by CMR based on improvement in LV systolic function
  • Acoramidis is the only oral, near-complete (≥90%) TTR stabilizer approved (Attruby) for ATTR-CM

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access